Nobuya Monden

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial

Takayuki Yoshino, Yasuhisa Hasegawa, Shunji Takahashi et al. · Japanese Journal of Clinical Oncology · 2013 · 73 citations · Full text

Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).

Naomi Kiyota, Makoto Tahara, Hirofumi Fujii et al. · Journal of Clinical Oncology · 2020 · 64 citations

Weekly Cisplatin, Surgical Oncology, Neoadjuvant Therapy +21

Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study

Nobuhiro Hanai, Yasushi Shimizu, Shin Kariya et al. · International Journal of Clinical Oncology · 2020 · 54 citations · Full text

Multicenter phase II study of an opioid-based pain control program for head and neck cancer patients receiving chemoradiotherapy

Sadamoto Zenda, Kazuto Matsuura, Hiroyuki Tachibana et al. · Radiotherapy and Oncology · 2011 · 49 citations

Pain Therapy, Neck Cancer Patients, Health Sciences +11